



Application No. 10/578,146  
Attorney Docket No. DHI-10857

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David R. Scholl *et al.*

Serial No.: 10/578,146

Group No.: 1648

Filed: 05/03/2006

Examiner: Blumel, B.P.

Entitled: **COMPOSITIONS AND METHODS FOR DETECTING SEVERE ACUTE  
RESPIRATORY SYNDROME CORONAVIRUS**

**INFORMATION DISCLOSURE STATEMENT**

**MS Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8**

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is being facsimile transmitted to the USPTO or is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 28, 2008

By: \_\_\_\_\_

Cliff Cannon-Cin

Dear Examiner Blumel:

The citations listed below, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. § 1.56 and § 1.97. The Examiner is requested to make these citations of official record in this application. References listed as 16-76 on the attached FORM PTO-1449 were already provided to the Office as part of an Information Disclosure Statement dated July 5, 2005, in the parent U.S. Application No. 10/699,936, filed November 3, 2003 (DHI-07986), which is relied upon for priority.

The following patents and printed publications are referred to in the body of the Specification:

- U.S. Patent No. 4,244,946 to Rivier *et al.*, "Water-soluble peptides affecting gonadal function (1981);
- U.S. Patent No. 4,946,778 to Ladner *et al.*, "Single polypeptide chain binding molecules (1990);

- U.S. Patent No. 5,270,163 to Gold *et al.*, “Methods for identifying nucleic acid ligands (1993);
- U.S. Patent No. 5,545,806 to Lonberg *et al.*, “Transgenic non-human animals for producing heterologous antibodies,” (1996);
- U.S. Patent No. 5,569,825 to Lonberg *et al.*, “Transgenic non-human animals capable of producing heterologous antibodies of various isotypes,” (1996);
- U.S. Patent No. 5,625,126 to Lonberg *et al.*, “Transgenic non-human animals for producing heterologous antibodies (1997);
- U.S. Patent No. 5,760,029 to Jadhav *et al.*, “Spirocycle integrin inhibitors,” (1998);
- U.S. Patent No. 6,252,043 to Hession *et al.*, “Vascular cell adhesion molecule (VCAM) polypeptides,” (2001);
- U.S. Patent No. 6,376,172 to Scholl *et al.*, “Mixed cell diagnostic systems,” (2002);
- U.S. Patent No. 6,472,206 to Scholl *et al.*, “In situ growth, freezing and testing of cultured cells,” (2002);
- U.S. Patent No. 6,610,474 to Huang, “Cells for detection of influenza and parainfluenza viruses,” (2003);
- EP Patent Application Publication No. 0 140 308 of Inouye *et al.*, “Regulation of gene expression by employing translational inhibition utilizing mRNA interfering complementary RNA,” (1985);
- Benbacer *et al.* (1997) “Interspecies aminopeptidase-*N* chimerase reveal species-specific receptor recognition by canine coronavirus, feline infectious peritonitis virus, and transmissible gastroenteritis virus,” J Virol, 71:734-737;
- Blondelle *et al.* (1995) “Soluble combinatorial libraries of organic, peptidomimetic and peptide diversities,” Trends Anal Chem, 14:83-92;
- Chaloner-Larsson *et al.* “Establishment and maintenance of a persistent infection of L132 cells by human coronavirus strain 229E,” (1981) Arch Virol, 69:117-129;
- Cole *et al.*, (1985) “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,” in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp 77-96;
- Compton *et al.* (1982) “Coronavirus species specificity: Murine coronavirus binds to a mouse-specific epitope on its carcinoembryonic antigen-related receptor glycoprotein,” J Virol, 66:7420-7428;.

- Cote *et al.* (1983) "Generation of human monoclonal antibodies reactive with cellular antigens," Proc Natl Acad Sci USA, 80:2026-2030;
- de Kruif *et al.* (1996) "Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes," FEBS Lett, 399:232-236;
- Delmas *et al.* (1992) "Aminopeptidase N is a major receptor for the enteropathogenic coronavirus TGEV," Nature, 357:417-420;
- Ding *et al.* (1995) "Synthesis and biological activity of oligosaccharide libraries," Adv Exp Med Biol, 376:261-269;
- Drosten *et al.* (2003) "Identification of a novel coronavirus in patients with severe acute respiratory syndrome," N Engl J Med, 348:1967-1976;
- Dveksler *et al.* (1991) "Cloning of the mouse hepatitis virus (MHV) receptor: Expression in human and hamster cell lines confers susceptibility to MHV," J Virol, 65:6881-6891;
- Dveksler *et al.* (1995) "Mouse hepatitis virus receptor activities of an MHVR/mph chimera and MHVR mutants lacking N-linked glycosylation of the N-terminal domain," J Virol, 69:543-546;
- Dveksler *et al.* (1996) "Expression of the recombinant anchorless N-terminal domain of mouse hepatitis virus (MHV) receptor makes hamster or human cells susceptible to MHV infection," J Virol, 70:4142-4145;
- Ecker and Crook (1995) "Combinatorial drug discovery: Which methods will produce the greatest value?" Bio/Technology 13:351-360;
- Fields and Noble (1990) "Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids," Intl Peptide Protein Res, 35:161-214;
- Fouchier *et al.* (2003) "Koch's postulates fulfilled for SARS virus," Nature, 423:240;
- Gleaves *et al.* (1992) "Detection of human cytomegalovirus in clinical specimens by centrifugation culture with a nonhuman cell line," J Clin Microbiol 30:1045-8;
- Gordon *et al.* (1994) "Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions," J Med Chem, 37:1385-1401;
- Hambor *et al.* (1988) "Functional consequences of anti-sense RNA-mediated inhibition of CD8 surface expression in a human T cell clone," J Exp Med, 168:1237-1245;

- Holmes and Lai (1996) "Coronaviridae: The Viruses and Their Replication," in *Fields Virology*, Third Edition, Lippincott-Raven, pp. 1075-1093;
- Holmes *et al.* (2001) "Coronaviruses," in *Fields Virology*, Fourth Edition, Lippincott Williams & Wilkins, Chapter 36, pp. 1187-1203;
- Huse *et al.* (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," *Science*, 246:1275-1281;
- Karaoglu *et al.* (1995) "Functional characterization of Ost3p. Loss of the 34-kD subunit of the *Saccharomyces cerevisiae* oligosaccharyltransferase results in biased underglycosylation of acceptor substrates," *J Cell Biol*, 130:567-577;
- Köhler and Milstein (1975) "Continuous cultures of fused cells secreting antibody of predefined specificity," *Nature*, 256:495-497;
- Koivunen *et al.* (1994) "Isolation of a highly specific ligand for the  $\alpha_5\beta_1$  integrin from a phage display library," *J Cell Biol*, 124: 373-380;
- Kolb *et al.* (1997) "Identification of residues critical for the human coronavirus 229E receptor function of human aminopeptidase N," *J Gen Virol*, 78:2795-2802;
- Kontoyiannis *et al.* (2003) "Aminopeptidase N inhibitors and SARS," *Lancet*, 361:1558;
- Kozbor *et al.* (1983) "The production of monoclonal antibodies from human lymphocytes," *Immunol Today*, 4:72;
- Ksiazek *et al.* (2003) "A novel coronavirus associated with severe acute respiratory syndrome," *N Engl J Med*, 348:1953-1966;
- Kuiken *et al.* (2003) "Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome," *Lancet*, 362:263-270;
- Liang *et al.* (1996) "Parallel synthesis and screening of a solid phase carbohydrate library," *Science*, 274:1520-1522;
- Look *et al.* (1989) "Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N," *J Clin Invest*, 83:1299-1307;
- Markus-Sekura (1988) "Techniques for using antisense oligodeoxyribonucleotides to study gene expression," *Anal Biochem*, 172:289-295;
- Marra *et al.* (2003) "The genome sequence of the SARS-associated coronavirus," *Science*, 300:1399-1404;

- Meienhofer, (1973) "Peptide synthesis: A review of the solid-phase method," in *Hormonal Proteins and Peptides*, Vol. II, Chapter 3, Academic Press (title and copyright pages only);
- Murphy and Chanock, (2001) "Immunization against viral diseases" in *Fields Virology*, Fourth Edition, Knipe and Howley, Lippincott Williams & Wilkins, Chapter 16, pp. 435-467;
- Nakabayashi *et al.* (1982) "Growth of human hepatoma cell lines with differentiated function in chemically defined medium," *Cancer Res*, 42: 3858-3863;
- Nakabayashi *et al.* (1984) "Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium," *Gann*, 75: 151-158 (abstract only);
- Nakabayashi *et al.* (1985) "Hormonal control of  $\alpha$ -fetoprotein secretion in human hepatoma cell lines proliferating in chemically defined medium," *Cancer Res*. 45:6379-6383;
- Palache *et al.* (1997) "Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs," *J Infect Dis*, 176(Suppl 1):S20-S23;
- Peiris *et al.* (2003) "Coronavirus as a possible cause of severe acute respiratory syndrome," *Lancet*, 361:1319-1325;
- Poon *et al.* (2003) "Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS)," *Clin Chem*, 49:953-955;
- Poutanen *et al.* (2003) "Identification of severe acute respiratory syndrome in Canada," *N Engl J Med*, 348:1995-2005;
- Rota *et al.* (2003) "Characterization of a novel coronavirus associated with severe acute respiratory syndrome," *Science*, 300:1394-1399;
- Sawicki and Sawicki (1995) "Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands," *Adv Exp Med Biol*, 380:499-506;
- Sawicki and Sawicki (1998) "A new model for coronavirus transcription," *Adv Exp Biol*, 440:215-219;
- Sawicki *et al.* (2001) "The RNA structures engaged in replication and transcription of the A59 strain of mouse hepatitis virus," *J Gen Virol*, 385-96;



- Snijder *et al.* (2003) "Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage," J Mol Biol, 331:991-1004;
- Thiel *et al.* (2003) "Mechanisms and enzymes involved in SARS coronavirus genome expression," J Gen Virol, 84:2305-2315;
- Tresnan *et al.* (1996) "Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup I," J Virol, 70:8669-8674;
- Ward *et al.* (1989) "Binding activities of a repertoire of single immunoglobulin variable domains secreted from *Escherichia coli*," Nature, 341:544-546;
- Wentworth *et al.* (2001) "Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): Influence of N-Linked glycosylation," J Virol, 75:9741-9752;
- Williams *et al.* (1990) "Purification of the 110-kilodalton glycoprotein receptor for mouse hepatitis virus (MHV)-A59 from mouse liver and identification of a nonfunctional, homologous protein in MHV-resistant SJL/J mice," J Virol, 64:3817-3823;
- Williams *et al.* (1991) "Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins," Proc Natl Acad Sci USA, 88:5533-5536;
- Winter and Harris (1993) "Humanized antibodies," Immunol Today, 14:243-246;
- Yeager *et al.* (1992) "Human aminopeptidase N is a receptor for human coronavirus 229E," Nature, 357:420-422 (abstract only);
- York *et al.* (1996) "The structures of arabinoxyloglucans produced by solanaceous plants," Carb Res, 285:99-128;
- Yount *et al.* (2003) "Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus," Proc Natl Acad Sci USA, 100:12995-13000;
- Yu *et al.* (2003) "Putative hAPN receptor binding sites in SARS CoV spike protein," Acta Pharmacol Sin, 24:481-488; and
- Zeng *et al.* (2003) "The complete genome sequence of severe acute respiratory syndrome coronavirus strain HKU-39849 (HK-39)," Exp Biol Med, 228:866-73.

Applicants have become aware of the following references, which may be material to the examination of this application:


- U.S. Patent No. 5,134,127 to Stella *et al.*, “Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof,” (1992);
- U.S. Patent No. 5,376,645 to Stella *et al.*, “Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof,” (1994);
- International Publication No. WO 2004/101781 of Hilgenfeld *et al.*, “Crystal structure of human coronavirus 229E main proteinase, and uses thereof for developing SARS inhibitors,” (2004);
- International Publication No. WO 2005/035712 of Baric *et al.*, “Methods and compositions for infectious cDNA of SARS coronavirus,” (2005); and
- “CAPTISOL® Solubility and so much more,” CyDex, Inc., Overland Park, KS (2001).

Also included for the Examiner’s convenience are the following patents and printed publications in which one or more of the Applicants are co-inventors or co-authors. These references, have been included for the sake of completeness:

- Gillim-Ross *et al.*, “Discovery of novel human and animal cells infected by the severe acute respiratory syndrome coronavirus by replication-specific multiplex reverse transcription-PCT,” J Clin Microbiol, 42:3196-3206 (2004).

This Information Disclosure Statement under 37 C.F.R. § 1.56 and § 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitute prior art.

Dated: April 28, 2008



Christine A. Lekutis  
Registration No. 51,934

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
415.904.6500